1. Home
  2. NKTR vs PRVA Comparison

NKTR vs PRVA Comparison

Compare NKTR & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$58.00

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

HOLD

Current Price

$19.39

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTR
PRVA
Founded
1990
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.5B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
NKTR
PRVA
Price
$58.00
$19.39
Analyst Decision
Strong Buy
Buy
Analyst Count
7
12
Target Price
★ $146.67
$31.17
AVG Volume (30 Days)
964.5K
★ 1.1M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 63.64
EPS
N/A
★ 0.09
Revenue
$307,711,000.00
★ $2,122,842,000.00
Revenue This Year
N/A
$18.19
Revenue Next Year
N/A
$10.72
P/E Ratio
★ N/A
$220.78
Revenue Growth
★ 86.00
22.26
52 Week Low
$33.40
$18.92
52 Week High
$109.00
$28.82

Technical Indicators

Market Signals
Indicator
NKTR
PRVA
Relative Strength Index (RSI) 33.78 33.72
Support Level $54.13 N/A
Resistance Level $76.63 $23.99
Average True Range (ATR) 3.68 0.57
MACD -1.13 0.05
Stochastic Oscillator 10.35 21.61

Price Performance

Historical Comparison
NKTR
PRVA

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

About PRVA Privia Health Group Inc.

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

Share on Social Networks: